Cargando…

Reduced Serum Levels of Bone Formation Marker P1NP in Psoriasis

Psoriasis is a chronic inflammatory disease of the skin and joints. More recent data emphasize an association with dysregulated glucose and fatty acid metabolism, obesity, elevated blood pressure and cardiac disease, summarized as metabolic syndrome. TNF-α and IL-17, central players in the pathogene...

Descripción completa

Detalles Bibliográficos
Autores principales: Mentzel, Julia, Kynast, Tabea, Kohlmann, Johannes, Kirsten, Holger, Blüher, Matthias, Simon, Jan C., Kunz, Manfred, Saalbach, Anja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517119/
https://www.ncbi.nlm.nih.gov/pubmed/34660638
http://dx.doi.org/10.3389/fmed.2021.730164
_version_ 1784583943172915200
author Mentzel, Julia
Kynast, Tabea
Kohlmann, Johannes
Kirsten, Holger
Blüher, Matthias
Simon, Jan C.
Kunz, Manfred
Saalbach, Anja
author_facet Mentzel, Julia
Kynast, Tabea
Kohlmann, Johannes
Kirsten, Holger
Blüher, Matthias
Simon, Jan C.
Kunz, Manfred
Saalbach, Anja
author_sort Mentzel, Julia
collection PubMed
description Psoriasis is a chronic inflammatory disease of the skin and joints. More recent data emphasize an association with dysregulated glucose and fatty acid metabolism, obesity, elevated blood pressure and cardiac disease, summarized as metabolic syndrome. TNF-α and IL-17, central players in the pathogenesis of psoriasis, are known to impair bone formation. Therefore, the relation between psoriasis and bone metabolism parameters was investigated. Two serum markers of either bone formation—N-terminal propeptide of type I procollagen (P1NP) or bone resorption—C-terminal telopeptide of type I collagen (CTX-I)—were analyzed in a cohort of patients with psoriasis vulgaris. In patients with psoriasis, P1NP serum levels were reduced compared to gender-, age-, and body mass index-matched healthy controls. CTX-I levels were indistinguishable between patients with psoriasis and controls. Consistently, induction of psoriasis-like skin inflammation in mice decreases bone volume and activity of osteoblasts. Moreover, efficient anti-psoriatic treatment improved psoriasis severity, but did not reverse decreased P1NP level suggesting that independent of efficient skin treatment psoriasis did affect bone metabolism and might favor the development of osteoporosis. Taken together, evidence is provided that bone metabolism might be affected by psoriatic inflammation, which may have consequences for future patient counseling and disease monitoring.
format Online
Article
Text
id pubmed-8517119
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85171192021-10-16 Reduced Serum Levels of Bone Formation Marker P1NP in Psoriasis Mentzel, Julia Kynast, Tabea Kohlmann, Johannes Kirsten, Holger Blüher, Matthias Simon, Jan C. Kunz, Manfred Saalbach, Anja Front Med (Lausanne) Medicine Psoriasis is a chronic inflammatory disease of the skin and joints. More recent data emphasize an association with dysregulated glucose and fatty acid metabolism, obesity, elevated blood pressure and cardiac disease, summarized as metabolic syndrome. TNF-α and IL-17, central players in the pathogenesis of psoriasis, are known to impair bone formation. Therefore, the relation between psoriasis and bone metabolism parameters was investigated. Two serum markers of either bone formation—N-terminal propeptide of type I procollagen (P1NP) or bone resorption—C-terminal telopeptide of type I collagen (CTX-I)—were analyzed in a cohort of patients with psoriasis vulgaris. In patients with psoriasis, P1NP serum levels were reduced compared to gender-, age-, and body mass index-matched healthy controls. CTX-I levels were indistinguishable between patients with psoriasis and controls. Consistently, induction of psoriasis-like skin inflammation in mice decreases bone volume and activity of osteoblasts. Moreover, efficient anti-psoriatic treatment improved psoriasis severity, but did not reverse decreased P1NP level suggesting that independent of efficient skin treatment psoriasis did affect bone metabolism and might favor the development of osteoporosis. Taken together, evidence is provided that bone metabolism might be affected by psoriatic inflammation, which may have consequences for future patient counseling and disease monitoring. Frontiers Media S.A. 2021-10-01 /pmc/articles/PMC8517119/ /pubmed/34660638 http://dx.doi.org/10.3389/fmed.2021.730164 Text en Copyright © 2021 Mentzel, Kynast, Kohlmann, Kirsten, Blüher, Simon, Kunz and Saalbach. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Mentzel, Julia
Kynast, Tabea
Kohlmann, Johannes
Kirsten, Holger
Blüher, Matthias
Simon, Jan C.
Kunz, Manfred
Saalbach, Anja
Reduced Serum Levels of Bone Formation Marker P1NP in Psoriasis
title Reduced Serum Levels of Bone Formation Marker P1NP in Psoriasis
title_full Reduced Serum Levels of Bone Formation Marker P1NP in Psoriasis
title_fullStr Reduced Serum Levels of Bone Formation Marker P1NP in Psoriasis
title_full_unstemmed Reduced Serum Levels of Bone Formation Marker P1NP in Psoriasis
title_short Reduced Serum Levels of Bone Formation Marker P1NP in Psoriasis
title_sort reduced serum levels of bone formation marker p1np in psoriasis
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517119/
https://www.ncbi.nlm.nih.gov/pubmed/34660638
http://dx.doi.org/10.3389/fmed.2021.730164
work_keys_str_mv AT mentzeljulia reducedserumlevelsofboneformationmarkerp1npinpsoriasis
AT kynasttabea reducedserumlevelsofboneformationmarkerp1npinpsoriasis
AT kohlmannjohannes reducedserumlevelsofboneformationmarkerp1npinpsoriasis
AT kirstenholger reducedserumlevelsofboneformationmarkerp1npinpsoriasis
AT bluhermatthias reducedserumlevelsofboneformationmarkerp1npinpsoriasis
AT simonjanc reducedserumlevelsofboneformationmarkerp1npinpsoriasis
AT kunzmanfred reducedserumlevelsofboneformationmarkerp1npinpsoriasis
AT saalbachanja reducedserumlevelsofboneformationmarkerp1npinpsoriasis